nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
|
Sato, Yasushi |
|
2015 |
75 |
3 |
p. 587-594 |
artikel |
2 |
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma
|
D’ Angelo, Sandra P. |
|
2015 |
75 |
3 |
p. 629-638 |
artikel |
3 |
A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer
|
Soejima, Kenzo |
|
2015 |
75 |
3 |
p. 513-519 |
artikel |
4 |
A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer
|
Choi, Dae Ro |
|
2015 |
75 |
3 |
p. 639-643 |
artikel |
5 |
A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine
|
Newman, Edward M. |
|
2015 |
75 |
3 |
p. 537-546 |
artikel |
6 |
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer
|
Yamazaki, Kentaro |
|
2015 |
75 |
3 |
p. 569-577 |
artikel |
7 |
Autophagy modulation: a target for cancer treatment development
|
Duffy, Alison |
|
2014 |
75 |
3 |
p. 439-447 |
artikel |
8 |
Dosing algorithm revisit for busulfan following IV infusion
|
Wang, Yanlin |
|
2015 |
75 |
3 |
p. 505-512 |
artikel |
9 |
Effect of axitinib on the QT interval in healthy volunteers
|
Ruiz-Garcia, Ana |
|
2015 |
75 |
3 |
p. 619-628 |
artikel |
10 |
Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease
|
Kenmotsu, Hirotsugu |
|
2015 |
75 |
3 |
p. 521-526 |
artikel |
11 |
Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial
|
Chen, Zhiyu |
|
2015 |
75 |
3 |
p. 547-557 |
artikel |
12 |
Erratum to: Does saturable formation of gemcitabine triphosphate occur in patients?
|
Tham, Lai-San |
|
2015 |
75 |
3 |
p. 657 |
artikel |
13 |
Intermittent dosing of aromatase inhibitors (AI) to improve tolerance in postmenopausal women: a rationale for future clinical studies
|
Salmon, R. |
|
2015 |
75 |
3 |
p. 653-655 |
artikel |
14 |
Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
|
Liu, Ying |
|
2015 |
75 |
3 |
p. 645-651 |
artikel |
15 |
Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus
|
Géresi, Krisztina |
|
2015 |
75 |
3 |
p. 609-618 |
artikel |
16 |
Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma
|
Joshi, Shweta |
|
2015 |
75 |
3 |
p. 595-608 |
artikel |
17 |
Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo
|
Liu, Yaping |
|
2014 |
75 |
3 |
p. 465-474 |
artikel |
18 |
Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer
|
Miyazaki, Tatsuya |
|
2014 |
75 |
3 |
p. 449-455 |
artikel |
19 |
Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
|
Han, Ji-Youn |
|
2014 |
75 |
3 |
p. 475-483 |
artikel |
20 |
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
|
Chang, T. C. |
|
2015 |
75 |
3 |
p. 579-586 |
artikel |
21 |
Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing
|
Nikanjam, Mina |
|
2015 |
75 |
3 |
p. 495-503 |
artikel |
22 |
Regulatory role of Lactobacillus acidophilus on inflammation and gastric dysmotility in intestinal mucositis induced by 5-fluorouracil in mice
|
Justino, Priscilla F. C. |
|
2015 |
75 |
3 |
p. 559-567 |
artikel |
23 |
Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival
|
Kasuga, Akiyoshi |
|
2014 |
75 |
3 |
p. 457-464 |
artikel |
24 |
Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study
|
Merchan, Jaime R. |
|
2015 |
75 |
3 |
p. 485-493 |
artikel |
25 |
The newly synthesized anticancer drug HUHS1015 is useful for treatment of human gastric cancer
|
Kaku, Yoshiko |
|
2015 |
75 |
3 |
p. 527-535 |
artikel |